Efficacy and safety of agomelatine 25-50 mg/day versus escitalopram 10-20 mg/day in severe generalized anxiety disorder

Dan Joseph Stein; Jon‐Paul Khoo; D.M. Van Ameringen; Cyril Höschl; Antti Ahokas; Max Bauer; István Bitter; Marek Jarema; S.N. Mosolov; L. Vavrušová; F. Picarel-Blanchot; Sophie Matharan; Valérie Olivier

doi:10.1016/s0924-977x(17)31762-5

Related publications

Article2016

Efficacy and safety of 2 doses of agomelatine (10 mg/day or 25 mg/day) versus placebo in generalized anxiety disorder

Dan Joseph Stein, Antti Ahokas, Marek Jarema, А С Аведисова, L. Vavrušová, Олег Чабан, Valérie Olivier, C. Gruget, F. Picarel-Blanchot, Christian de Bodinat

Article2018

12-week double-blind randomized multicenter study of efficacy and safety of agomelatine (25–50 mg/day) versus escitalopram (10–20 mg/day) in out-patients with severe generalized anxiety disorder

Dan Joseph Stein, Jon‐Paul Khoo, Antti Ahokas, Marek Jarema, Michael Van Ameringen, L. Vavrušová, Cyril Höschl, Michael Bauer, István Bitter, Sergey Mosolov, Valérie Olivier, Sophie Matharan, F. Picarel-Blanchot, Christian de Bodinat

Article2017

Efficacy and safety of agomelatine (10 or 25 mg/day) in non-depressed out-patients with generalized anxiety disorder: A 12-week, double-blind, placebo-controlled study

Dan Joseph Stein, Antti Ahokas, Marek Jarema, А С Аведисова, L. Vavrušová, Олег Чабан, C. Gruget, Valérie Olivier, F. Picarel-Blanchot, Christian de Bodinat

Article2008

Efficacy of Agomelatine in Generalized Anxiety Disorder

Dan Joseph Stein, Antti Ahokas, Christian de Bodinat

Article2021

Efficacy of Agomelatine 25–50 mg for the Treatment of Anxious Symptoms and Functional Impairment in Generalized Anxiety Disorder: A Meta-Analysis of Three Placebo-Controlled Studies

Dan Joseph Stein, Jon‐Paul Khoo, F. Picarel-Blanchot, Valérie Olivier, Michael Van Ameringen